| Company Name | Pfizer |
|---|---|
| Protocol Number | A5481107 |
| Title of Study | Treatment Patterns And Clinical Outcomes Among Taiwanese Patients Receiving Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. |
| Primary Objective | 1.To describe the demographic and clinical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications 2.To summarize adjuvant therapies received for the treatment of early or locally advanced breast cancer (Stages 0-IIIa) 3.To describe treatments received in the advanced/ metastatic setting, before and after palbociclib combination use. 4.To describe dosing and dose changes, interruptions, delays, and discontinuations associated with palbociclib use in clinical practice |
| Number of Sites | 5 |
| Period of Study | From：2018/09/18 to：2023/02/01 |
| Number of Patients | 50人 |
| IRB Approval Date | NTUH:2018/06/15 |
| Publication Plan / Date | 2023/08/01 |
